MediGene receives US-patent regarding cervical cancer vaccine

07-Mar-2002 - March 6, 2001. The German-American biopharmaceutical company MediGene AG announced today that the US patent office has issued US patent No. 6,352,696. entitled "Papillomavirus truncated L1 protein and fusion protein constructs" regarding vaccines to treat tumors induced by human papilloma virus ...

MediGene increases revenues in the first nine months significantly

23-Nov-2001 - In the first nine months of 2001 the biopharmaceutical company MediGene (Neuer Markt: MDG) has successful driven forward its corporate development. Currently, MediGene has seven drug candidates in different stages of clinical development. These drug candidates were developed using different ...

Broad US-patent issued to MediGene

Patent protects novel methods for production of therapeutic viruses

19-Sep-2001 - The German-American biopharmaceutical company MediGene (NMarkt: MDG) announced today a significant addition to its intellectual property portfolio with the grant of US-Patent US 6,277,621. This patent gives MediGene broad protection covering the use of bacterial artificial chromosomes (BAC) ...

MEDIGENE AND AVENTIS START CLINICAL TRIAL FOR VACCINE AGAINST MALIGNANT MELANOMA

05-Jul-2001 - The biopharmaceutical company MediGene AG (NMarkt: MDG) announced today the start of a phase 1/2 clinical trial for a vaccine against malignant melanoma developed together with Aventis Pharma AG. The therapeutic vaccination is based on gene transfer by so-called adeno-associated viruses (AAV). ...

MEDIGENE FOCUSES ON CORE COMPETENCIES

Spin off MediGenomix sold to Eurofins Scientific

29-May-2001 - The internationally operating biopharmaceutical company MediGene AG (NMarkt: MDG) announced today that it sells its 30% stake in MediGenomix GmbH to the bioanalytical company EUROFINS SCIENTIFIC AG. Financial details were not disclosed. The innovative bioanalytical company MediGenomix, a ...

US-PATENT FOR MEDIGENE’S GENE TRANSFER TECHNOLOGY ISSUED

30-Apr-2001 - The biopharmaceutical company MediGene AG (NMarkt: MDG) announced today the issuance of US-Patent US 6,207,453. The granted patent protects a method which allows a safe and efficient integration of foreign DNA into target cells using recombinant Adeno Associated Viruses (rAAV). MediGene’s ...

US-PATENT FOR MEDIGENE’S GENE TRANSFER TECHNOLOGY ISSUED

25-Apr-2001 - he biopharmaceutical company MediGene AG (NMarkt: MDG) announced today the issuance of US-Patent US 6,207,453. The granted patent protects a method which allows a safe and efficient integration of foreign DNA into target cells using recombinant Adeno Associated Viruses (rAAV). MediGene’s ...

MEDIGENE: POSITIVE PHASE 1 DATA - PHASE 2 TRIAL FOR MEDIGENE´S NOVEL ANTICANCER THERAPEUTIC BEING PREPARED

Final study report for G207 to treat brain cancer submitted to the FDA

07-Mar-2001 - The biopharmaceutical company MediGene AG (NMarkt: MDG) announced today that its wholly owned subsidiary MediGene, Inc. based in San Diego, USA has submitted a final study report of its phase 1 clinical trial for G207, a novel anticancer therapeutic for the treatment of brain tumors to the FDA, ...

US-PATENT FOR MEDIGENE’S TUMOR VACCINE TECHNOLOGY ISSUED

01-Feb-2001 - The biopharmaceutical company MediGene AG (NMarkt: MDG) announced today the issuance of US-Patent US 6,171,595. The granted patent protects MediGene’s method for using recombinant adeno-associated viruses (AAV) to produce tumor vaccines. On the basis of the so-called AAV-technology MediGene is ...

CLOSING HELD FOR ACQUISITION OF NEUROVIR THERAPEUTICS, INC.

16-Jan-2001 - The German biopharmaceutical company MediGene AG (NMarkt: MDG) announced today the closing of the acquisition of NeuroVir Therapeutics, Inc. (San Diego, CA), a biopharmaceutical company developing modified herpes simplex viruses (HSV) for use in cancer therapy. Currently NeuroVir has two product ...